START FREE TRIAL

Kenvue Tylenol Lawsuits Cloud $48.7 Billion Deal

Kenvue (NYSE:KVUE) woke up on July 13 with an old legal threat suddenly alive again. A federal appeals court...

Merck’s $11 BillionBio-Techne Deal Looks Strategic, But The Debt Trade-Off Is REAL

Merck KGaA (ETR:MRK) has made a bold early move under new CEO Kai Beckmann. The German drug, chemicals, and...

AbbVie’s $11 Billion Eczema Gamble Is Bigger Than Skin

AbbVie Inc. (NYSE:ABBV) may be close to buying Apogee Therapeutics for about $10.9 billion in cash. That is a...

Moderna’s Flu Shot Won Over FDA Advisers—But Can It Win Back America?

Moderna (NASDAQ:MRNA) just landed a regulatory moment that people will argue about far beyond Wall Street. An FDA advisory...

Incyte Acquisition Watch: The $2 Billion Star Therapeutics Deal That Could Change Its Story

Incyte Corporation (NASDAQ:INCY) is back in the biotech deal spotlight. The company is reportedly nearing an agreement to acquire...

Novo Nordisk Earnings Pre-Mortem: The Beat May Not Be Enough!

Novo Nordisk reports first-quarter 2026 earnings on May 6, and the market is walking into the print with unusually...

Everyone Thinks Eli Lilly Is A Weight-Loss Stock. That’s The Trap

Eli Lilly (NYSE:LLY) is having one of those rare market moments where everyone thinks they understand the story. Weight-loss...

Amazon Earnings Pre-Mortem: THIS Is What’s Making Investors Nervous!!

Amazon reports earnings this week, and the setup looks strong on the surface. Consensus expects first-quarter revenue of roughly $177...

This Telehealth Stock Rally By RFK Jr. Looks Like Policy; It’s Actually A Margin SHIFT

Hims & Hers Health (NYSE:HIMS) did not report a surprise quarter, launch a blockbuster product, or raise guidance when...

Eli Lilly’s Foundayo & The GLP-1 Pivot From Innovation to Access Control!

Most coverage of Eli Lilly’s(NYSE:LLY) Foundayo launch has treated it like the next round in the company’s fight with...

The “Boring” Healthcare Stock Making A $5 Billion POWER MOVE!

The market loves excitement. But money is often made in boredom. That is what makes Gilead Sciences (NASDAQ:GILD) such...

This Biotech Stock Already Has A Blockbuster; So Why Is It ACQUIRING Another Rare Disease Asset?

There are biotech stories that look obvious, and then there are biotech stories that quietly change shape right in...